8-K: INmune Bio Set to Join Russell 3000 Index, Boosting Visibility

INmune Bio Inc. will be included in the Russell 3000 Index effective July 1, 2024, which is expected to increase the company's visibility and broaden its shareholder base.

Summary

• INmune Bio Inc., a clinical-stage biotechnology company, is set to join the Russell 3000 Index.
• The inclusion will be effective at the open of US equity markets on July 1, 2024.
• The Russell 3000 Index includes the 4,000 largest US stocks based on market capitalization.
• Membership in the Russell 3000 Index also means automatic inclusion in the Russell 1000 or 2000 indexes, as well as growth and value style indexes.
• FTSE Russell determines index membership based on market capitalization and style attributes.
• Approximately $10.5 trillion in assets are benchmarked against the Russell US indexes as of December 2023.

Sentiment

Score: 8

Explanation: The document is positive due to the company's inclusion in the Russell 3000 Index, which is a significant milestone. However, the document also includes standard risk disclosures for a clinical-stage biotech company.

Positives

• Inclusion in the Russell 3000 Index is expected to increase the company's visibility.
• The company anticipates a broader shareholder base due to the index inclusion.
• The Russell indexes are widely used by investment managers and institutional investors.
• The inclusion is a testament to the hard work and dedication of the company's team.

Risks

• Clinical trials for INmune Bio's product platforms are in early stages, and there is no assurance of specific outcomes.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of additional funding for operations and research is a risk.
• Regulatory approval for the company's products is not guaranteed.
• The company's business, research, product development, marketing and distribution plans and strategies are subject to risks and uncertainties.

Future Outlook

The company expects that inclusion in the Russell 3000 Index will increase its visibility within the investment community and broaden its shareholder base. However, the company acknowledges that clinical trials are in early stages and there is no assurance of specific outcomes.

Management Comments

• Dr. Raymond J. Tesi, CEO of INmune Bio, stated that the inclusion in the Russell 3000 Index is a testament to the hard work and dedication of the entire team.
• Dr. Tesi also stated that the inclusion underscores the company's commitment to advancing its innovative immunology and inflammation platforms.
• Fiona Bassett, CEO of FTSE Russell, commented that annual rebalancing plays a vital role in establishing accurate benchmarks.

Industry Context

This announcement is positive for INmune Bio as inclusion in a major index like the Russell 3000 can lead to increased investor interest and potentially higher trading volumes. It also reflects the company's growth and market capitalization reaching a level that qualifies it for inclusion in the index. This is a common milestone for growing biotech companies.

Comparison to Industry Standards

• Inclusion in the Russell 3000 is a common benchmark for growing companies, particularly in the biotech sector.
• Many companies in the biotech space strive for inclusion in major indexes as it can lead to increased visibility and investment.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals are examples of biotech companies that are included in the Russell 1000 index, which is a subset of the Russell 3000.
• The $10.5 trillion benchmarked against the Russell indexes highlights the significance of this index for institutional investors.

Stakeholder Impact

• Shareholders are likely to view this as a positive development, potentially leading to increased stock value.
• Employees may see this as a validation of their work and the company's progress.
• The company's increased visibility may attract new investors and partners.

Next Steps

• INmune Bio will officially join the Russell 3000 Index on July 1, 2024.
• The company will continue its clinical trials for its product platforms.

Key Dates

Keywords

Russell 3000 Index, FTSE Russell, Index Inclusion, Market Capitalization, Biotechnology, Immunology, Inflammation, Clinical Trials, NASDAQ, INMB